MARKET

XOMA

XOMA

XOMA Royalty Corporation
NASDAQ
26.18
+0.93
+3.68%
After Hours: 26.18 0 0.00% 16:10 12/30 EST
OPEN
25.47
PREV CLOSE
25.25
HIGH
27.08
LOW
25.12
VOLUME
615.63K
TURNOVER
--
52 WEEK HIGH
39.92
52 WEEK LOW
18.35
MARKET CAP
324.19M
P/E (TTM)
35.08
1D
5D
1M
3M
1Y
5Y
1D
H.C. Wainwright remains bullish on Xoma following creative Takeda deal
TipRanks · 7h ago
XOMA: Expanding Royalty Portfolio and Capital-Efficient Partnerships Underpin Buy Rating
TipRanks · 8h ago
Takeda, XOMA ink new royalty agreement; amend existing deal
Seeking Alpha · 11h ago
Xoma, Takeda execute royalty sharing transaction, amend Mezagitamab agreement
TipRanks · 11h ago
XOMA Royalty Amends Its Collaboration, Originally Established In 2006, With Takeda Through Strategic Royalty Share Transaction
Benzinga · 11h ago
XOMA ROYALTY CORP - RETAINS LOW ROYALTY AND $13 MLN IN MILESTONES FOR MEZAGITAMAB
Reuters · 11h ago
XOMA ROYALTY: ENTITLED TO PAYMENTS ASSOCIATED WITH NINE DEVELOPMENT-STAGE ASSETS HELD WITHIN TAKEDA'S EXTERNALIZED ASSETS PORTFOLIO
Reuters · 11h ago
XOMA ROYALTY AND TAKEDA EXECUTE STRATEGIC ROYALTY SHARING TRANSACTION AND AMEND EXISTING AGREEMENT FOR MEZAGITAMAB
Reuters · 11h ago
More
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

Webull offers XOMA Royalty Corp stock information, including NASDAQ: XOMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XOMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XOMA stock methods without spending real money on the virtual paper trading platform.